Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

13G Filing: EcoR1 Capital and aTyr Pharma Inc (LIFE)

Page 1 of 7

aTyr Pharma Inc (NASDAQ:LIFE): Oleg Nodelman’s EcoR1 Capital filed an amended 13D.

You can check out EcoR1 Capital’s latest holdings and filings here.

Please follow EcoR1 Capital (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about EcoR1 Capital or update its stock holdings.

Oleg Nodelman
Oleg Nodelman
EcoR1 Capital

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
EcoR1 Capital 0 4,642,396 0 4,642,396 4,642,396 15.3%
Oleg Nodelman 0 4,642,396 0 4,642,396 4,642,396 15.3%
EcoR1 Capital Fund Qualified 0 3,767,786 0 3,767,786 3,767,786 12.5%
Oleg Nodelman
Oleg Nodelman
EcoR1 Capital

Page 1 of 7 – SEC Filing

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act
of 1934
(Amendment No. 1)

aTYR Pharma, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

002120103

(CUSIP Number)

August 28, 2017

(Date of Event Which Requires Filing
of this Statement)

Check the appropriate box to designate the rule pursuant
to which this Schedule is filed:

[X]       Rule
13d-1(b)

[X]       Rule
13d-1(c)

[ ]       Rule
13d-1(d)

* The remainder of this cover page shall be filled out for
a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent
amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page
shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”)
or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however,
see the Notes).

Potential persons who are to respond to the collection
of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

1
Follow Atyr Pharma Inc
Trade (LIFE) Now!
Page 1 of 7